Drug firm Lupin today reported a consolidated net profit of Rs 164.84 crore for the quarter ended December 31, 2009, showing an increase of 39.9 per cent compared to the same period a year ago.
The company had reported a net profit of Rs 117.78 crore in the third quarter last fiscal, it said in a statement.
During the quarter under review, the company's total income rose to Rs 1,255.45 crore, registering a growth of over 30 per cent compared to the same period last fiscal.
Speaking about the company's performance, Lupin Chief Financial Officer Ramesh Swaminathan said, "We have achieved an all round growth this year and our sales across all geographies have registered a good growth."
The company is planning to set up three plants in Madhya Pradesh for manufacturing formulations in dermatology and opthalmology segments.
Lupin has recently got clearance from the US Food and Drug Administration for its Mandideep production unit, where the drug regulator had found discrepancies in manufacturing standards last year.